false
0001651407
0001651407
2024-08-12
2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): August 12, 2024
Checkpoint
Therapeutics, Inc.
(Exact Name of Registrant as Specified in
charter)
Delaware |
|
001-38128 |
|
47-2568632 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
95
Sawyer Road, Suite
110,
Waltham, MA 02453
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
CKPT |
Nasdaq
Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial
Condition.
On August 12, 2024, Checkpoint Therapeutics, Inc.
issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2024.
A copy of such press release is being furnished as Exhibit 99.1 to this report.
The information, including Exhibit 99.1, in this
Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in
such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: August 12, 2024 |
Checkpoint Therapeutics, Inc. |
|
(Registrant) |
|
|
|
By |
/s/ James F. Oliviero |
|
|
James F. Oliviero |
|
|
President and Chief Executive Officer |
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1651407/000110465924088117/image_001.jpg)
Checkpoint Therapeutics Reports Second Quarter
2024 Financial Results and Recent Corporate Updates
Waltham, MA – August 12, 2024 –
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company,
today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates.
James F. Oliviero, President and Chief Executive
Officer of Checkpoint, said, “We’ve made significant recent progress as we seek approval of cosibelimab as a potential new
treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (‘’cSCC’’) who are
not candidates for curative surgery or curative radiation. We are pleased to have reached alignment with the U.S. Food and Drug Administration
(‘‘FDA’’) on our strategy to potentially address the deficiencies identified in the complete response letter
(‘‘CRL’’) received last December. Shortly thereafter, we resubmitted our Biologics License Application (“BLA”),
which was accepted by the FDA for review as a complete response to the CRL. We look forward to working with the FDA in advance of the
Prescription Drug User Fee Act (‘‘PDUFA’’) goal date of December 28, 2024, to potentially deliver this important
therapeutic option to cutaneous squamous cell carcinoma patients and their families.”
Recent Corporate Updates:
| · | Checkpoint
submitted a BLA to the FDA in January 2023 seeking approval of cosibelimab as a potential
new treatment for patients with metastatic or locally advanced cSCC who are not candidates
for curative surgery or curative radiation. In December 2023, the FDA issued a CRL for the
cosibelimab BLA. The CRL only cited findings that arose during a multi-sponsor inspection
of Checkpoint’s third-party contract manufacturing organization (“CMO”)
as approvability issues to address in a BLA resubmission. The CRL did not state any concerns
about the clinical data package, safety, or labeling for the approvability of cosibelimab. |
| · | In
June 2024, Checkpoint reached alignment with the FDA on its BLA resubmission strategy for
cosibelimab and resubmitted the BLA shortly thereafter. |
| · | In
July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its
BLA for cosibelimab as a complete response to the CRL issued in December 2023 and set a PDUFA
goal date of December 28, 2024. |
| · | Also
in July 2024, Checkpoint announced a collaboration to explore the combined therapeutic potential
of cosibelimab, its anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s
Immuncell-LC, an innovative autologous Cytokine Induced Killer T cell therapy composed of
cytotoxic T lymphocytes and natural killer T cells. |
| · | Also
in July 2024, Checkpoint completed a registered direct offering priced At-the-Market under
Nasdaq rules and a concurrent private placement of warrants to purchase Checkpoint common
stock, for total gross proceeds of approximately $12.0 million. |
Financial Results:
| · | Cash
Position: As of June 30, 2024, Checkpoint’s cash and cash equivalents totaled $5.0
million, compared to $11.2 million at March 31, 2024 and $4.9 million at December 31, 2023,
a decrease of $6.2 million for the quarter and an increase of $0.1 million, year-to-date.
After the end of the second quarter, Checkpoint raised gross proceeds of approximately $12.0
million in a registered direct offering completed in July 2024. |
| · | R&D
Expenses: Research and development expenses for the second quarter of 2024 were $4.5
million, compared to $13.9 million for the second quarter of 2023, a decrease of $9.4 million.
Research and development expenses for the second quarter of 2024 included $0.6 million of
non-cash stock expenses, compared to $0.2 million for the second quarter of 2023. |
| · | G&A
Expenses: General and administrative expenses for the second quarter of 2024 were $2.2
million, compared to $2.3 million for the second quarter of 2023, a decrease of $0.1 million.
General and administrative expenses for the second quarter of 2024 included $0.6 million
of non-cash stock expenses, compared to $0.8 million for the second quarter of 2023. |
| · | Net
Loss: Net loss attributable to common stockholders for the second quarter of 2024 was
$6.7 million, or $0.18 per share, compared to a net loss of $16.5 million, or $1.05 per share,
in the second quarter of 2023. Net loss for the second quarter of 2024 included $1.2 million
of non-cash stock expenses, compared to $1.0 million for the second quarter of 2023. |
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. is a clinical-stage
immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients
with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential differentiated anti-PD-L1
antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic
cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer
agent, olafertinib, a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment
for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress
Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended, that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited
to, statements regarding our resubmission of our BLA for cosibelimab and review thereof, our belief that the BLA resubmission potentially
addresses all the issues in the CRL, our belief about the comprehensive nature of our BLA resubmission and reaching alignment with the
FDA on our cosibelimab BLA resubmission strategy, our ability to work with our third-party CMO and the FDA to adequately address the
issues raised in the CRL and execute on a pathway forward for the potential marketing approval of cosibelimab, the adequacy of the responses
to the inspection issues submitted to FDA by our third-party CMO, our projections of regulatory review timelines, the commercial potential
of cosibelimab, if approved, and the potential differentiation of cosibelimab, including a potentially favorable safety profile as compared
to the currently available anti-PD-1 therapies and the dual mechanism of action of cosibelimab translating into potential enhanced efficacy.
Factors that could cause our actual results to differ materially include the following: the risks and uncertainties associated with the
regulatory review process; uncertainties regarding the timeline of FDA review of the resubmitted BLA; any inability to successfully work
with the FDA to find a satisfactory solution to address any concerns in a timely manner or at all during the review process for the BLA,
including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA; our,
and our third party CMO’s, ability to adequately address the issues raised in the CRL; issues associated with any facility inspection
or re-inspection of our third party CMO or otherwise during the review process for the BLA; the risk that our third-party CMO will not
meet deadlines, and/or comply with applicable regulations; whether the FDA accepts the data and results as included in the BLA resubmission
at levels consistent with the published results, or at all; our ability to execute a partnering or other relationship to enable the commercialization
of cosibelimab, if approved, on acceptable terms, if at all; the risk that topline and interim data remains subject to audit and verification
procedures that may result in the final data being materially different from the topline or interim data we previously published; the
risk that safety issues or trends will be observed in the clinical trial when the full safety dataset is available and analyzed; the
risk that a positive primary endpoint does not translate to all, or any, secondary endpoints being met; risks that regulatory authorities
will not accept an application for approval of cosibelimab based on data from the Phase 1 clinical trial; the risk that the clinical
results from the Phase 1 clinical trial will not support regulatory approval of cosibelimab to treat cSCC or, if approved, that cosibelimab
will not be commercially successful; risks related to our chemistry, manufacturing and controls and contract manufacturing relationships;
risks related to our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks related
to our need for substantial additional funds; other uncertainties inherent in research and development; our dependence on third-party
suppliers; government regulation; patent and intellectual property matters; competition; unfavorable market or other economic conditions;
and our ability to achieve the milestones we project, including the risk that the evolving and unpredictable Russia/Ukraine conflict
and COVID-19 pandemic delay achievement of those milestones. Further discussion about these and other risks and uncertainties can be
found in our Annual Report on Form 10-K, and in our other filings with the U.S. Securities and Exchange Commission. The information contained
herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information
in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.
Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes
in events, conditions or circumstances on which any such statement is based, except as required by law. This press release and prior
releases are available at www.checkpointtx.com. The information found on our website is not incorporated by reference into this press
release and is included for reference purposes only.
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
checkpoint@gregoryfca.com
CHECKPOINT THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
|
|
June 30, 202 4 |
|
|
December 31, 2023 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
4,951 |
|
|
$ |
4,928 |
|
Prepaid expenses and other current assets |
|
|
678 |
|
|
|
450 |
|
Other receivables - related party |
|
|
41 |
|
|
|
- |
|
Total current assets |
|
|
5,670 |
|
|
|
5,378 |
|
Total Assets |
|
$ |
5,670 |
|
|
$ |
5,378 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
18,115 |
|
|
$ |
15,485 |
|
Accounts payable and accrued expenses - related party |
|
|
3,179 |
|
|
|
2,815 |
|
Common stock warrant liabilities |
|
|
125 |
|
|
|
125 |
|
Total current liabilities |
|
|
21,419 |
|
|
|
18,425 |
|
Total Liabilities |
|
|
21,419 |
|
|
|
18,425 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity (Deficit) |
|
|
|
|
|
|
|
|
Common Stock ($0.0001 par value), 175,000,000 and 80,000,000 shares authorized as of June 30, 2024 and December 31, 2023, respectively |
|
|
|
|
|
|
|
|
Class A common shares, 700,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023 |
|
|
- |
|
|
|
- |
|
Common shares, 41,631,500 and 27,042,035 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively |
|
|
4 |
|
|
|
3 |
|
Common stock issuable, 0 and 1,492,915 shares as of June 30, 2024 and December 31, 2023, respectively |
|
|
- |
|
|
|
3,419 |
|
Additional paid-in capital |
|
|
316,195 |
|
|
|
297,864 |
|
Accumulated deficit |
|
|
(331,948 |
) |
|
|
(314,333 |
) |
Total Stockholders’ Equity (Deficit) |
|
|
(15,749 |
) |
|
|
(13,047 |
) |
Total Liabilities and Stockholders’ Equity (Deficit) |
|
$ |
5,670 |
|
|
$ |
5,378 |
|
CHECKPOINT THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts)
(Unaudited)
| |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Revenue - related party | |
$ | 41 | | |
$ | 31 | | |
$ | 41 | | |
$ | 66 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 4,480 | | |
| 13,945 | | |
| 12,977 | | |
| 29,771 | |
General and administrative | |
| 2,234 | | |
| 2,281 | | |
| 4,685 | | |
| 4,573 | |
Total operating expenses | |
| 6,714 | | |
| 16,226 | | |
| 17,662 | | |
| 34,344 | |
Loss from operations | |
| (6,673 | ) | |
| (16,195 | ) | |
| (17,621 | ) | |
| (34,278 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 3 | | |
| 31 | | |
| 7 | | |
| 74 | |
(Loss) gain on common stock warrant liabilities | |
| - | | |
| (357 | ) | |
| | | |
| 7,209 | |
Foreign currency exchange loss | |
| - | | |
| - | | |
| (1 | ) | |
| - | |
Total other income (expense) | |
| 3 | | |
| (326 | ) | |
| 6 | | |
| 7,283 | |
Net Loss | |
$ | (6,670 | ) | |
$ | (16,521 | ) | |
$ | (17,615 | ) | |
$ | (26,995 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per Share: | |
| | | |
| | | |
| | | |
| | |
Basic and diluted net loss per common share outstanding | |
$ | (0.18 | ) | |
$ | (1.05 | ) | |
$ | (0.51 | ) | |
$ | (1.97 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted weighted average number of common shares outstanding | |
| 36,526,268 | | |
| 15,700,324 | | |
| 34,728,623 | | |
| 13,735,646 | |
v3.24.2.u1
Cover
|
Aug. 12, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 12, 2024
|
Entity File Number |
001-38128
|
Entity Registrant Name |
Checkpoint
Therapeutics, Inc.
|
Entity Central Index Key |
0001651407
|
Entity Tax Identification Number |
47-2568632
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
95
Sawyer Road
|
Entity Address, Address Line Two |
Suite
110
|
Entity Address, City or Town |
Waltham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02453
|
City Area Code |
781
|
Local Phone Number |
652-4500
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
CKPT
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Checkpoint Therapeutics (NASDAQ:CKPT)
過去 株価チャート
から 7 2024 まで 8 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
過去 株価チャート
から 8 2023 まで 8 2024